期刊
EXPERT OPINION ON DRUG SAFETY
卷 15, 期 11, 页码 1501-1513出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14740338.2016.1226281
关键词
HIV; pregnancy; antiretroviral therapy; infant safety; surveillance programs
资金
- NIH/NIAID [T32 5T32AI007433-21]
- Pediatric HIV/AIDS Cohort Study (PHACS)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- NIH
- Harvard T. H. Chan School of Public Health [HD052102]
- Tulane University School of Medicine [HD052104]
Introduction: The use of antiretroviral therapy (ART) in pregnancy to prevent vertical HIV transmission has been one of the most successful public health programs in the last decade. As a result, an unprecedented number of women are taking ART at conception and during pregnancy. Given few randomized studies evaluating safety of different ART regimens in pregnancy, ongoing drug safety surveillance is critical.Areas covered: This review aims to provide a rationale for ART drug safety surveillance, describe changing patterns of ART use and summarize current surveillance efforts in both low-resource and high-resource settings. Additionally, biostatistical approaches to and challenges in analysis of observational surveillance data are discussed.Expert opinion: The global landscape of ART use in pregnancy is rapidly increasing and evolving. Any increase in adverse effects of in-utero exposure to ART has the potential to reduce the impact of improvements in infant morbidity and mortality gained from decreased vertical HIV transmission. ART drug safety surveillance should therefore be a critical piece of programs to prevent mother to child transmission in both high- and low-resource settings. Current surveillance efforts could be strengthened with long-term follow-up of exposed children, pooling of data across cohorts and standardized approaches to analysis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据